EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer

Bohao Zhang, Haozhe Zhang, Yanru Qin

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl25447 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Bohao Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou Hospital of Zhengzhou University, 450000 Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Tumor Suppressor Protein p53, Mutation, Molecular Targeted Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial Cancer (EC) is one of the most common gynecological malignancies, ranking first in developed countries and regions. The occurrence and development of EC is closely associated with genetic mutations. TP53 mutation, in particular, can lead to the dysfunction of numerous regulatory factors and alteration of the tumor microenvironment (TME). The changes in the TME subsequently promote the development of tumors and assist in immune escape by tumor cells, making it more challenging to treat EC and resulting in a poor prognosis. Therefore, it is important to understand the effects of TP53 mutation in EC and to conduct further research in relation to the targeting of TP53 mutations. This article reviews current research progress on the role of TP53 mutations in regulating the TME and in the mechanism of EC tumorigenesis, as well as progress on drugs that target TP53 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsTumor Suppressor Protein p53MutationMolecular Targeted TherapyHumansFemaleTumor MicroenvironmentAntineoplastic Agents

Stichwörter der Autor:innen

TP53 mutationsendometrial cancerp53 proteintargeted therapies

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Zhengzhou Hospital of Zhengzhou University, 450000 Zhengzhou, Henan, China.

Zitieren

APA

Zhang, B., Zhang, H., & Qin, Y. (2025). A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl25447

Vancouver

Zhang B, Zhang H, Qin Y. A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl25447

BibTeX
@article{Zhang2025,
  author = {Zhang, Bohao and Zhang, Haozhe and Qin, Yanru},
  title = {A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl25447}
}
Kostenlos starten →